Month: September 2020

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.19311-37-6,3-Bromotetrahydrofuran,as a common compound, the synthetic route is as follows.

Example 204 1-(4-fluoro-3,5-dimethylbenzyl)-6-methyl-2-(piperazin-1-yl)-4-((tetrahydrofuran-3-yl)oxy)-1H-benzo[d]imidazole tert-Butyl 4-(4-bromo-1-(4-fluoro-3,5-dimethylbenzyl)-6-methyl-1H-benzo[d]imidazol-2-yl)piperazine-1-carboxylate (100 mg, 0.19 mmol, 1.00 eq), potassium hydroxide (21 mg, 0.38 mmol, 2.00 eq), tris(dibenzylideneacetone)dipalladium(0) (7 mg, 0.015 mmol Pd, 0.08 eq Pd), and 2-di-tert-butylphosphino-3,4,5,6-tetramethyl-2′,4′,6′-triisopropyl-1,1′-biphenyl (Me4-t-BuXPhos) (14 mg, 0.030 mmol, 0.16 eq) were weighed into a vial. The vial was sealed, evacuated, and refilled with argon. The evacuation/refill process was repeated two additional times. A solution of 1,4-dioxane/water (1:1 v/v) (0.4 mL)-which had been degassed using three evacuation/refill cycles-was added. The vial was then heated to 90 C. and the progress of the reaction was monitored by LCMS. When the starting material had been completely consumed, the reaction mixture was allowed to cool to room temperature. Potassium hydroxide (21 mg, 0.38 mmol, 2.00 eq), hexadecyltrimethylammonium bromide (7 mg, 0.02 mmol), and 3-bromotetrahydrofuran (57 mg, 0.38 mmol) were added. The vial was then heated to 100 C. and the progress of the reaction was monitored by LCMS. When the intermediate tert-butyl 4-(1-(4-fluoro-3,5-dimethylbenzyl)-4-hydroxy-6-methyl-1H-benzo[d]imidazol-2-yl)piperazine-1-carboxylate had been completely consumed, the reaction mixture was allowed to cool to room temperature. CH2Cl2 (5 mL) and saturated aqueous NH4Cl (5 mL) were added. The resulting biphasic mixture was stirred for ten min before being passed through a phase separator. To the filtrate thus obtained was added trifluoroacetic acid (1 mL). The resulting solution was stirred at room temperature and the progress of the reaction was monitored by LCMS. When the intermediate tert-butyl 4-(1-(4-fluoro-3,5-dimethylbenzyl)-6-methyl-4-((tetrahydrofuran-3-yl)oxy)-1H-benzo[d]imidazol-2-yl)piperazine-1-carboxylate had been completely consumed, the reaction mixture was concentrated in vacuo. The residual oil was purified by reverse phase preparative HPLC. The title compound was obtained as a white solid as its corresponding trifluoroacetate salt (30 mg, 29% yield). 1H NMR (400 MHz, CD3OD) delta 6.93 (s, 1H), 6.92 (s, 1H), 6.78 (2s ovlp, 2H), 5.34 (s, 2H), 5.29 (m, 1H), 4.05 (m, 3H), 3.91 (td, J=8.3, 4.6 Hz, 1H), 3.64 (m, 4H), 3.41 (m, 4H), 2.41 (s, 3H), 2.37 (m, 1H), 2.24 (m, 1H), 2.21 (2s ovlp, 6H). MS (ESI) (M+H+) m/z=439.30. LCMS Ret time (UV 214/254): 1.188 min.

19311-37-6, As the paragraph descriping shows that 19311-37-6 is playing an increasingly important role.

Reference£º
Patent; Vanderbilt University; Fesik, Steve; Waterson, Alex; Burns, Michael; Sun, Qi; Phan, Jason; Salovich, James M.; Abbott, Jason R.; Little, Andrew; (159 pag.)US10501421; (2019); B1;,
Tetrahydrofuran – Wikipedia
Tetrahydrofuran | (CH2)3CH2O – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.14631-43-7,2-Cyanotetrahydrofuran,as a common compound, the synthetic route is as follows.

14631-43-7, Preparation c-130 2-{6-[2-(5-Methyl-2-phenyl-oxazol-4-yl)-ethoxy]-pyridin-3-ylmethyl}-tetrahydro-furan-2-carbonitrile Sodium bis(trimethylsilyl)amide (1.8 mL, 1.79 mmol) was added to a solution of tetrahydro-furan-2-carbonitrile (0.17 g, 1.79 mmol) in anhydrous tetrahydrofuran (6 mL) under an atmosphere of nitrogen at -78 C. The resulting yellow solution was stirred for 50 minutes, and then a solution of 5-iodomethyl-2-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-pyridine (0.25 g, 0.596 mmol) in anhydrous tetrahydrofuran (3 mL) was added to the enolate solution. The mixture was stirred at -78 C. for 1.5 hours, and quenched with saturated aqueous ammonium chloride (5 mL). The aqueous phase was extracted with ethyl acetate (3*50 mL), and the combined organic extracts washed with water (30 mL), dried (anhydrous magnesium sulfate), filtered, and concentrated in vacuo to give the crude product. The residue was purified by flash column chromatography (7% to 45% ethyl acetate/hexanes) to afford the title compound (0.11 g, 46%) as a white solid. LRMS (m/z): 390 (M+H)+. 1H NMR (CDCl3, 300 MHz), delta 8.03 (1H, d, J=2.5 Hz), 7.96 (2H, m), 7.56 (1H, dd, J=8.5, 2.5 Hz), 7.40 (3H, m), 6.68 (1H, d, J=8.5 Hz), 4.54 (2H, m), 3.96 (2H, m), 3.00 (4H, m), 2.33 (5H, d, J=3.2 Hz), 1.92 (2H, m).

As the paragraph descriping shows that 14631-43-7 is playing an increasingly important role.

Reference£º
Patent; Pfizer Inc; US2005/187266; (2005); A1;,
Tetrahydrofuran – Wikipedia
Tetrahydrofuran | (CH2)3CH2O – PubChem

4344-84-7, 5-Oxotetrahydrofuran-2-carboxylic acid is a Tetrahydrofurans compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Step 2: 5-Oxo-tetrahydro-furan-2-carboxylic acid (5-methyl-pyridin-2-yl)-amide; Oxalyl chloride (0.252 g, 1.63 mmol) in DCM (5 mL) was added slowly to a stirred solution of 5-oxotetrahydrofuran-2-carboxylic acid (Step 1) (0.215 g, 1.65 mmol) in DCM (10 ml) and DMF (50 mul) at 0¡ã C. After 3 hrs at ambient temperature, gas evolution had subsided. DIPEA (0.64, 4.95 mmol) was added followed by the addition of 2-amino-5-picoline (0.357 g, 3.3 mmol) in DCM (5 mL). The reaction mixture was kept at ambient temperature for 3 hrs. Water (0.5 mL) was added and the reaction mixture was concentrated in vacuo. The residue was purified by column chromatography (silica gel, eluting with a gradient consisting of 0-40percent MeOH in DCM) to give the title compound as a colorless oil (0.138 g). 1H NMR (500 MHz, CDCl3) delta 8.74 (br s, 1H), 8.13 (d, 1H), 8.08 (d, 1H), 7.54 (dd, 1H), 4.99 (t, 1H), 2.71 (m, 1H), 2.63 (m, 2H), 2.48 (m, 1H), 2.31 (s, 3H).

4344-84-7, 4344-84-7 5-Oxotetrahydrofuran-2-carboxylic acid 636468, aTetrahydrofurans compound, is more and more widely used in various.

Reference£º
Patent; AstraZeneca AB; US2010/93757; (2010); A1;,
Tetrahydrofuran – Wikipedia
Tetrahydrofuran | (CH2)3CH2O – PubChem

87219-29-2, (S)-Benzyl (5-oxotetrahydrofuran-3-yl)carbamate is a Tetrahydrofurans compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

87219-29-2, In a 500 ml round-bottomed flask phenylmethyl [(3S)-5-oxotetrahydro-3-furanyl]carbamate (4.3 g, 18.28 mmol, available from Sigma -Aldrich No. 419249) was dissolved in water (100 ml) and acetone (100 ml) and to this solution CS2CO3 (10.72 g, 32.9 mmol) was added and the reaction left under stirring at room temperature for 5 hours. The solution was then transferred into a separatory funnel and washed with EtOAc (2 x 50 ml). The aqueous phase was then acidified to pH = 2 by the addition of a 2 M HCl aqueous solution and then extracted with EtOAc (5 x 100 mis). The organic phase was dried (Na2SO4) and solvent removed under reduced pressure to give the title compound Dl (3.78 g) as a white solid. MS: (ES/+) m/z: 254 (M+l). C12H15NO5 requires 253. 1H NMR (400 MHz, DMSO-J6) delta (ppm): 12.11 (bs, 1 H), 7.41-7.07 (m, 5 H), 5.17-4.92 (m, 2 H), 3.95-3.62 (m, 1 H), 3.42- 3.22 (m, 2 H), 2.55-2.40 (m, 1 H), 2.34-2.23 (m, 1 H)

The synthetic route of 87219-29-2 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; GLAXO GROUP LIMITED; ALVARO, Giuseppe; AMANTINI, David; CASTIGLIONI, Emiliano; DI FABIO, Romano; PAVONE, Francesca; WO2010/63662; (2010); A1;,
Tetrahydrofuran – Wikipedia
Tetrahydrofuran | (CH2)3CH2O – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.88675-24-5,Tetrahydrofuran-3-amine,as a common compound, the synthetic route is as follows.,88675-24-5

A mixture of (6-(4-((6-chloropyridazin-3-yl)methoxy)-2-oxopyridin-l (2H)-yl)-7,8- dihydronaphthalen-2-yl)methyl methanesulfonate (350 mg, 0.739 mmol), tetrahydrofuran-3- amine (77 mg, 0.886 mmol) and K2CO3 (306 mg, 2.216 mmol) in N, N-dimethylformamide (DMF) (15 mL) was stirred at 80 ¡ãC for 6 hr, then solvent was removed to give the residue which was purified by prep HPLC and chiral prep HPLC to give 4-[(6-chloropyridazin-3- yl)methoxy]-l – {6-[(tetrahydrofuran-3-ylamino)methyl]-3,4-dihydronaphthalen-2-yl}pyridin- 2(lH)-one hydrochloride as a yellow solid (peak 1 , 65 mg, 1 1.2percent yield): 1H NMR (400 MHz, CD3OD) delta ppm 8.05 (d, J = 7.2 Hz, 1H), 7.99 (d, J = 8.8 Hz, 1H), 7.93 (d, J = 8.8 Hz, 1H), 7.41-7.38 (m, 2H), 7.30-7.28 (m, 1H), 6.89-6.87 (m, 1H), 6.80 (s, 1H), 6.63 (d, J = 2.4 Hz, 1H), 5.64 (s, 2H), 4.23-4.21 (m, 2H), 4.06-3.95 (m, 3H), 3.86-3.82 (m, 1H), 3.75-3.72 (m, 1H), 3.1 1 -3.09 (m, 2H), 2.76-2.68 (m, 2H), 2.43-2.41 (m, 1H), 2.15-2.10 (m, 1H); ES- LCMS m/z 465 (M+H), and 4-[(6-chloropyridazin-3-yl)methoxy]-l – {6-[(tetrahydrofuran-3- ylamino)methyl]-3,4-dihydronaphthalen-2-yl}pyridin-2(lH)-one hydrochloride as a yellow solid (peak 2, 49.3 mg, 8.5percent yield): 1H NMR (400 MHz, CD3OD) delta ppm 7.98-7.93 (m, 3H), 7.41-7.38 (m, 2H), 7.30-7.28 (m, 1H), 6.85-6.79 (m, 2H), 6.61 -6.60 (m, 1H), 5.64 (s, 2H), 4.23-4.22 (m, 2H), 4.05-4.00 (m, 3H), 3.87-3.83 (m, 1H), 3.73-3.71 (m, 1H), 3.13-3.09 (m, 2H), 2.73-2.67 (m, 2H), 2.41-2.39 (m, 1H), 2.12-2.10 (m, 1H); ES-LCMS m/z 465 ( +H)+. Chiral HPLC method Instrument: Thar 80 Column: AS 250mm*20mm, 20um Mobile phase: A: Supercritical C02, B: MeOH, A: B =55:45 at 80mL/min Column Temp: 38¡ãC Nozzle Pressure: lOOBar Nozzle Temp: 60¡ãC Evaporator Temp: 20¡ãC Trimmer Temp: 25¡ãC Wavelength: 220nm

The synthetic route of 88675-24-5 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; GLAXOSMITHKLINE LLC; QIN, Donghui; CHRISTENSEN, IV, Siegfried Benjamin; WU, Chengde; ZHANG, Zhiliu; YU, Haiyu; YUAN, Jiangxing; LIN, Xiaojuan; XU, Shanli; LV, Maoyun; YAO, Chen; LI, Lei; HUANG, Xing; GAO, Min; WO2013/166621; (2013); A1;,
Tetrahydrofuran – Wikipedia
Tetrahydrofuran | (CH2)3CH2O – PubChem

453-20-3, 3-Hydroxytetrahydrofuran is a Tetrahydrofurans compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated,453-20-3

To a suspension of sodium hydride (1.2 equiv, 60% by weight in mineral oil) in THF (0.3 M) under nitrogen atmosphere was added tetrahydrofuran-3-ol (1.5 equiv) in THF (0.6 M) at 0 C. The resulting reaction mixture was stirred at 0 C. for 20 min. A solution of 6-(2,4-dichloro-7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-methylbenzo[d]oxazole (1 equiv) in THF (0.6 M) was added and the resulting reaction mixture was stirred at room temperature for 3 h. The reaction mixture was quenched with saturated aqueous ammonium chloride solution (0.6 M) and the organic solvents were removed under reduced pressure. The resulting residue was diluted with water and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was evaporated under reduced pressure and the crude product was purified by silica gel chromatography (15% ethyl acetate in petroleum ether) to afford the title compound (83% yield). MS (ESI) m/z 501.1 [M+H]+.

The synthetic route of 453-20-3 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; Signal Pharmaceutical LLC; Calabrese, Andrew Antony; Jeffy, Brandon; Robinson, Dale; Zhu, Dan; Huang, Dehua; Elsner, Jan; Boylan, John; Tehrani, Lida; Nagy, Mark A.; Moghaddam, Mehran Fallah; Raheja, Raj Kumar; Erdman, Paul; Narla, Rama K.; Harris, Roy L.; Tran, Tam Minh; Riggs, Jennifer; Ning, Yuhong; US2014/200206; (2014); A1;,
Tetrahydrofuran – Wikipedia
Tetrahydrofuran | (CH2)3CH2O – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.184950-35-4,(Tetrahydrofuran-3-yl)methanamine hydrochloride,as a common compound, the synthetic route is as follows.

184950-35-4, 5- (2-phenoxyethyloxymethyl) isoxazole-3-carboxylic acid (1.40 g, 5.3 mmol), Tetrahydrofuran-3-ylmethylamine hydrochloride (0.88 g, 6.4 mmol), Triethylamine (0.65 g, 6.4 mmol) And 1-hydroxybenzotriazole (0.08 g, 0.64 mmol) were added to chloroform (amylene addition product) (20 mL). To the mixture, 1-Ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride (1.23 g, 6.4 mmol) was added at room temperature, After stirring overnight, And concentrated under reduced pressure. Dilute hydrochloric acid was added to the concentrate, Extracted twice with ethyl acetate. The organic layer was washed with saturated brine, After drying with anhydrous sodium sulfate, And concentrated under reduced pressure. The residue was subjected to silica gel column chromatography, Represented by the following equation N- (tetrahydrofuran-3-ylmethyl) -5- (2-phenoxyethyloxymethyl) isoxazole-3-carboxamide (Hereinafter referred to as present amide compound (149)) 1.60 g was obtained.

184950-35-4 (Tetrahydrofuran-3-yl)methanamine hydrochloride 17750392, aTetrahydrofurans compound, is more and more widely used in various.

Reference£º
Patent; SUMITOMO CHEMICAL COMPANY LIMITED; SUMITA, YUSUKE; (264 pag.)JP2015/51963; (2015); A;,
Tetrahydrofuran – Wikipedia
Tetrahydrofuran | (CH2)3CH2O – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.219823-47-9,(R)-Tetrahydrofuran-3-yl 4-methylbenzenesulfonate,as a common compound, the synthetic route is as follows.

(mixture of stereoisomers) (4-fluoro-2-hydroxyphenyl)-9-{[2-(trifluoromethoxy)phenyl]acetyl}-1,3,9-triazaspiro[5.5]- undecan-2-one (100 mg, 208 pmol, Intermediate 15), (3R)-oxolan-3-yl 4-methylbenzene-1 – sulfonate (75.5 mg, 312 pmol) and potassium carbonate (1 15 mg, 0.831 mmol) were mixed in dimethylformamide (1.2 ml_) and heated to 100 13 for 5 hours. The reaction was cooled down to room temperature, filtered and purified by preperative HPLC (Method 1 1) to give the title compound 65.0 mg (52 % yield). LC-MS (Method 4): Rt = 1.09 min; MS (ESIpos): m/z = 552 [M+H]+ 1H-NMR (400 MHz, DMSO-d6) d [ppm]: 1.153 (0.98), 1.201 (1.22), 1.237 (2.54), 1.267 (2.20), 1.359 (2.88), 1.382 (2.54), 1.533 (1.66), 1.565 (1.46), 1.598 (1.56), 1.631 (1.32), 1.833 (0.83), 1.849 (1.12), 1.866 (1.37), 1.883 (1.17), 1.898 (1.07), 1.916 (1.12), 1.935 (1.37), 1.951 (1.71), 1.967 (1.80), 1.996 (0.88), 2.026 (0.78), 2.041 (0.73), 2.047 (1.32), 2.062 (1.71), 2.068 (0.73), 2.076 (0.59), 2.083 (1.46), 2.097 (0.98), 2.103 (0.59), 2.1 18 (0.54), 2.187 (1.41), 2.202 (2.00), 2.220 (2.29), 2.238 (1.90), 2.428 (16.00), 2.518 (11.56), 2.522 (7.02), 2.673 (2.05), 2.947 (1.22), 2.967 (1.17), 3.1 19 (0.88), 3.154 (1.61), 3.183 (2.29), 3.212 (1.27), 3.285 (3.37), 3.343 (7.22), 3.375 (4.00), 3.489 (0.68), 3.521 (1.71), 3.544 (3.41), 3.553 (4.15), 3.583 (4.10), 3.594 (3.85), 3.636 (2.88), 3.646 (7.37), 3.652 (10.29), 3.663 (5.66), 3.667 (3.46), 3.673 (5.02), 3.677 (3.27), 3.681 (4.10), 3.684 (4.73), 3.688 (4.10), 3.714 (3.80), 3.719 (4.24), 3.728 (3.32), 3.740 (4.59), 3.757 (8.05), 3.761 (6.34), 3.778 (8.00), 3.793 (6.98), 3.834 (3.46), 3.844 (3.76), 3.859 (1.85), 3.877 (2.34), 3.886 (2.29), 3.903 (1.90), 3.915 (1.66), 3.946 (1.71), 3.987 (2.05), 4.023 (0.88), 5.063 (2.39), 5.101 (2.29), 5.106 (2.15), 5.1 1 1 (2.29), 5.1 16 (2.15), 5.121 (1.41), 5.125 (1.12), 6.440 (6.15), 6.665 (5.66), 6.732 (1.46), 6.738 (1.80), 6.752 (3.85), 6.759 (3.66), 6.766 (2.93), 6.773 (3.80), 6.780 (2.20), 6.787 (1.61), 6.794 (1.51), 6.886 (3.12), 6.891 (3.17), 6.898 (2.88), 6.908 (2.63), 6.915 (3.22), 6.920 (3.22), 6.927 (2.63), 7.207 (6.10), 7.215 (12.34), 7.226 (9.85), 7.253 (10.68), 7.259 (8.68), 7.279 (3.66), 7.331 (2.00), 7.339 (4.00), 7.345 (4.00), 7.354 (3.56), 7.363 (3.95), 7.376 (1.76), 7.382 (1.22), 7.481 (3.61), 7.483 (4.20), 7.502 (4.68), 7.799 (5.95), 7.804 (1.80), 7.816 (1.76), 7.820 (5.32).

219823-47-9, As the paragraph descriping shows that 219823-47-9 is playing an increasingly important role.

Reference£º
Patent; BAYER AKTIENGESELLSCHAFT; GRAHAM, Keith; AIGUABELLA FONT, Nuria; HEINRICH, Tobias; BRAeUER, Nico; LANGE, Martin; BADER, Benjamin; PRECHTL, Stefan; LIENAU, Philip; NOWAK-REPPEL, Katrin; POTZE, Lisette; STEUBER, Holger; NIU, Haitao; WANG, Qiuwen; (248 pag.)WO2020/48827; (2020); A1;,
Tetrahydrofuran – Wikipedia
Tetrahydrofuran | (CH2)3CH2O – PubChem

88675-24-5, Tetrahydrofuran-3-amine is a Tetrahydrofurans compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated,88675-24-5

EXAMPLE 44: (2i?)-2-(6-fluoro-3-oxopyrrolo[4,3,2-Je][2,6]naphthyridin- 4(l/f,3/f,5H)-yl)-3-methyl-Lambda/-(tetrahydrofuran-3-yl)butanamide[0410] To an 8 mL scintillation vial equipped for stirring was added (i?)-2-(6-fluoro-3- oxopyrrolo[4,3,2-(ie][2,6]naphthyridin-4(lH,3H,5H)-yl)-3-methylbutanoic acid (15 mg, 0.051 mmol). DMF (0.5 mL), tetrahydrofuran-3 -amine (0.077, 6.7mg), HOBt (11.83 mg, 0.077 mmol), EDC (14.81 mg, 0.077 mmol) and N,N-dimethylpyridin-4-amine (9.44 mg, 0.077 mmol) were added and the solution was stirred at 25¡ãC for 4 h. The reaction mixture was purified via preparative mass trigger LC-MS (AcCN/H2O, 20-50percent). The fractions were collected and lyophilized to afford the title compound as a white solid (7.3mg, 39.3percent). 1H NMR (400 MHz, CD3OD) delta 0.93 (d, J=6.57 Hz, 3 H) 1.04 (dd, J=6.57, 2.78 Hz, 3 H) 1.74 -1.95 (m, 1 H) 2.21 (d, J=7.83 Hz, 1 H) 2.42 – 2.54 (m, 1 H) 3.50 – 3.67 (m, 1 H) 3.69 – 3.97 (m, 3 H) 4.37(td, J=3.85, 1.89 Hz, 1 H) 4.96 – 5.12 (m, 2 H) 5.36 – 5.52 (m, 1 H) 7.86 (s, 1 H) 8.17 (d, J=3.28 Hz, 1 H). [M+H] calc’d for Ci8H2IFN4O3, 361; found, 361.4.

As the paragraph descriping shows that 88675-24-5 is playing an increasingly important role.

Reference£º
Patent; TAKEDA PHARMACEUTICAL COMPANY LIMITED; DONG, Qing; LAWSON, John, David; WALLACE, Michael, B.; KANOUNI, Toufike; WO2010/144486; (2010); A1;,
Tetrahydrofuran – Wikipedia
Tetrahydrofuran | (CH2)3CH2O – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.219823-47-9,(R)-Tetrahydrofuran-3-yl 4-methylbenzenesulfonate,as a common compound, the synthetic route is as follows.

To a solution of toluene-4-sulfonic acid (R)-(tetrahydro-furan-3-yl) ester (1.5 g, 6.2 mmol) and Cs2C03 (1 .83 g, 5.6 mmol) in DMF (20 mL) was added 1 H-pyrazole-4-carboxylic acid ethyl ester (789 mg, 5.6 mol). The mixture was kept at 80C for 14 h. The volatiles were removed in vacuo and the residue was extracted with EtOAc (50 mL). The combined organic layers were washed with H20, dried over Na2S04 and evaporated to dryness. Flash chromatography (silica, petroleum ether: EtOAc 3:1 ) gave reagent 2 as a solid (1.07 g, 91 %). 1H NMR (CDCI3) delta 7.97 (s, 1 H), 7.90 (s, 1 H), 4.95-5.00 (m, 1 H), 4.27 (q, J = 6.4 Hz, 2 H), 4.01 -4.15 (m, 3 H), 3.90-3.96 (m, 1 H), 2.43-2.52 (m, 1 H), 2.27-2.34 (m, 1 H), 1.33 (t, J = 6.4 Hz, 3 H)., 219823-47-9

219823-47-9 (R)-Tetrahydrofuran-3-yl 4-methylbenzenesulfonate 13837325, aTetrahydrofurans compound, is more and more widely used in various.

Reference£º
Patent; H. LUNDBECK A/S; ESKILDSEN, J¡ãrgen; WO2014/49133; (2014); A1;,
Tetrahydrofuran – Wikipedia
Tetrahydrofuran | (CH2)3CH2O – PubChem